Login | Register
Profile | Log out
logo

  • Home
  • News
  • Opinion
  • Other
    • Market Updates
    • Explainers
    • Satire
  • About
  • Contact Us
    • Contact
    • Get Covered
    • Posting Guidelines
  • Subscribe
Submit An Article

Aroa Biosurgery (ASX:ARX)

  • Home
  •  
  • Aroa Biosurgery (ASX:ARX)



  • Most Read
  • Latest Comments
  • AROA secures 2027 US reimbursement certainty for Symphony products
    • News

    RBA and ASIC up the ante on blockchain project, ASX writes off millions
    Public
  • AROA secures 2027 US reimbursement certainty for Symphony products
    • Satire

    Australia to close borders to Omicron Persei 8
    Public
  • AROA secures 2027 US reimbursement certainty for Symphony products
    • Opinion

    The New Criterion: will the listed sanitiser stocks clean up – or clean out – investors?
    Public
  • AROA secures 2027 US reimbursement certainty for Symphony products
    • Opinion

    Is this the most hated company on the ASX?
    Public
  • AROA secures 2027 US reimbursement certainty for Symphony products
    Opening a new frontier in treating Parkinson’s disease
    • Review
    • November 11, 2022
  • Tremors from the FTX collapse continue to be felt as DigitalX sells off 15% Bitcoin holdings
    • Review
    • January 10, 2023
  • AUDC stablecoin gathers momentum as Novatti confirms integration with XRP Ledger
    • Review
    • June 9, 2022
  • PharmAust completes dosing first cohort for MND treatment, patients respond positively
    • Review
    • January 6, 2023
  • Is this the most hated company on the ASX?
    • Review
    • August 16, 2019

Latest Articles

  • AROA secures 2027 US reimbursement certainty for Symphony products
    • News

  • IPO Watch July: Aroa Biosurgery
    IPO Watch July: Aroa Biosurgery
    • Opinion

  • The New Criterion: the IPOs forging ahead in the coronavirus era
    The New Criterion: the IPOs forging ahead in the coronavirus era
    • Opinion

    • News

    AROA secures 2027 US reimbursement certainty for Symphony products

    Reimbursement certainty remains an important factor in the adoption of advanced wound care products across the United States, where payment arrangements influence how healthcare providers access and use treatments. A recent announcement by Aroa Biosurgery (ASX:ARX) highlighted this point, with the company reporting that the US Centers for Medicare & Medicaid Services (CMS) will maintain

    Read More
    Public

Login or register for free to access unlimited reading

Register Now!
  • News

  • Opinion

  • Satire

  • About

  • Contact Us

  • Subscribe

The content published on this website is solely for general information purposes and is not to be construed as financial advice. Should you seek financial advice you should consult with an appropriately qualified person. Opinions expressed on this site are subject to change without notice and The Sentiment who produced this content is under no obligation to keep the information current. The Sentiment, affiliated companies & associates may have a conflict of interest with companies discussed on the website due to commercial arrangements, for example they may be shareholders in the company, be engaged by them to assist in investor communications or receive commission/brokerage for funds raised.

Copyright © 2020 The Sentiment. All rights reserved.
Subscribe

Enter your email address below to subscribe to The Sentiment’s weekly newsletter, highlighting the top news, research, opinion and satire articles shaping ASX investor sentiment.

The Sentiment respects your privacy and will not spam you. View our privacy policy here.